Amorphous solid dispersion with increased gastric solubility in tandem with oral disintegrating tablets: a successful approach to improve the bioavailability of atorvastatin

References

• Stegemann S, Leveiller F, Franchi D, et al. When poor solubility becomes an issue: from early stage to proof of concept. Eur J Pharm Sci 2007;31:249–261
   PubMed Web of Science ®Google Scholar
• Lennernäs H. Human jejunal effective permeability and its correlation with preclinical drug absorption models. J Pharm Pharmacol 1997;49:627–638
   PubMed Web of Science ®Google Scholar
• Wu X, Whitfield LR, Stewart BH. Atorvastatin transport in the caco-2 cell model: contributions of P-glycoprotein and the protonmonocarboxylic acid co-transporter. Pharm Res 2000;17:209–215
   PubMed Web of Science ®Google Scholar
• Anwar M, Warsi MH, Mallick N, et al. Enhanced bioavailability of nano-sized chitosan–atorvastatin conjugate after oral administration to rats. Eur J Pharm Sci 2011;44:241–249
   PubMed Web of Science ®Google Scholar
• Maurya D, Belgamwar V, Tekade A. Microwave induced solubility enhancement of poorly water soluble atorvastatin calcium. J Pharm Pharmacol 2010;62:1599–1606
   PubMed Web of Science ®Google Scholar
• Arunkumar N, Deecaraman M, Rani C, et al. Preparation and solid state characterization of atorvastatin nanosuspension for enhanced solubility and dissolution. Int J PharmTech Res 2009;1:1725–1730
   Google Scholar
• Palem CR, Patel S, Pokharkar VB. Solubility and stability enhancement of atorvastatin by cyclodextrin complexation. PDA J Pharm Sci Technol 2009;63:217–225
   PubMedGoogle Scholar
• Kadu PJ, Kushare SS, Thacker DD, Gattani SG. Enhancement of oral bioavailability of atorvastatin calcium by self-emulsifying drug delivery systems (SEDDS). Pharm Dev Technol 2011;16:65–74
   PubMed Web of Science ®Google Scholar
• Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci 1971;60:1281–1302
   PubMed Web of Science ®Google Scholar
• Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersion. Eur J Pharm Biopharm 2000;50:47–60
   PubMed Web of Science ®Google Scholar
• Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 1997;86:1–12
   PubMed Web of Science ®Google Scholar
• Rumondor AC, Ivanisevic I, Bates S, et al. Evaluation of drug-polymer miscibility in amorphous solid dispersion systems. Pharm Res 2009;26:2523–2534
   PubMed Web of Science ®Google Scholar
• Gao Y, Carr RA, Spence JK, et al. A pH-dilution method for estimation of biorelevant drug solubility along the gastrointestinal tract: application to physiologically based pharmacokinetic modeling. Mol Pharm 2010;7:1516–1526
   PubMed Web of Science ®Google Scholar
• Jung J-Y, Yoo SD, Lee S-H, et al. Enhanced solubility and dissolution rate of itraconazole by a solid dispersion technique. Int J Pharm 1999;187:209–218
   PubMed Web of Science ®Google Scholar
• Onoue S, Kojo Y, Aoki Y, et al. Physicochemical and pharmacokinetic characterization of amorphous solid dispersion of tranilast with enhanced solubility in gastric fluid and improved oral bioavailability. Drug Metab Pharmacokinet 2012;27:379–387
   PubMed Web of Science ®Google Scholar
• Beak I-H, Kim M-S. Improved supersaturation and oral absorption of dutasteride by amorphous solid dispersions. Chem Pharm Bull 2012;60:1468–1473
   PubMed Web of Science ®Google Scholar
• Khan S, Kataria P, Nakhat P, Yeole P. Taste masking of ondansetron hydrochloride by polymer carrier system and formulation of rapid-disintegrating tablets. AAPS PharmSciTech 2007;8:E127–E133
   Web of Science ®Google Scholar
• FDA. Guidance for industry orally disintegrating tablets. USA: U.S. Department of Health and Human Services; 2008
   Google Scholar
• Lau YY, Okochi H, Huang Y, Benet LZ. pharmacokinetic of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of frist-pass effects from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos 2006;34:1175–1181
   PubMed Web of Science ®Google Scholar
• Kerc J. Stable pharmaceutical formulation comprising a HMG-CoA reductase inhibitor; 2004, Google Patents
   Google Scholar
• Shete G, Puri V, Kumar L, Bansal AK. Solid state characterization of commercial crystalline and amorphous atorvastatin calcium samples. AAPS PharmSciTech 2010;11:598–609
   PubMed Web of Science ®Google Scholar
• Coleman NJ, Craig DQM. Modulated temperature differential scanning calorimetry: a novel approach to pharmaceutical thermal analysis. Int J Pharm 1996;135:13–29
   Web of Science ®Google Scholar
• Kim M-S, Jin S-J, Kim J-S, et al. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm 2008;69:454–465
   PubMed Web of Science ®Google Scholar
• Konno H, Taylor LS. Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J Pharm Sci 2006;95:2692–2705
   PubMed Web of Science ®Google Scholar
• Rumondor ACF, Marsac PJ, Stanford LA, Taylor LS. Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture. Mol Pharm 2009;6:1492–1505
   PubMed Web of Science ®Google Scholar
• Rumondor ACF, Ivanisevic I, Bates S, et al. Evaluation of drug-polymer miscibility in amorphous solid dispersion systems. Pharm Res 2009;26:2523–2534
   PubMed Web of Science ®Google Scholar
• Khan FN, Dehghan MH. Enhanced bioavailability of atorvastatin calcium from stabilized gastric resident formulation. AAPS PharmSciTech 2011;12:1077–1086
   PubMed Web of Science ®Google Scholar
• Loftsson T, Fri∂riksdóttir H, Gu∂mundsdóttir TK. The effect of water-soluble polymers on aqueous solubility of drugs. Int J Pharm 1996;127:293–296
   Web of Science ®Google Scholar
• McConnell EL, Basit AW, Murdan S. Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments. J Pharm Pharmacol 2008;60:63–70
   PubMed Web of Science ®Google Scholar
• Löbenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm 2000;50:3–12
   PubMed Web of Science ®Google Scholar